Angang Steel (00347) issues profit warning, expecting a net loss attributable to shareholders of approximately 4.077 billion yuan in 2025, a year-on-year decrease of 42.75%.
Ansteel Group (00347) announced that it expects the net loss attributable to the company's shareholders for the 12 months ending on December 31, 2025 to decrease compared to the same period in 2024. The net loss attributable to the company's shareholders is expected to be around RMB 4.077 billion, a decrease of approximately RMB 3.045 billion, representing a reduction of about 42.75% year-on-year; the net loss attributable to the company's shareholders after deducting non-recurring gains and losses is expected to be around RMB 4.228 billion, narrowing by about 41.29% compared to the same period last year; the basic loss per share is around RMB 0.435.
Angang Steel (00347) announced that it is expected that the net loss attributable to the company's shareholders (referred to as "the Group") for the 12 months ending December 31, 2025, will decrease compared to the same period in 2024. The net loss attributable to the company's shareholders is expected to be around RMB 4.077 billion, with a decrease of approximately RMB 3.045 billion, a decrease of about 42.75% year-on-year; the net loss attributable to the company's shareholders after deducting non-recurring gains and losses is expected to be around RMB 4.228 billion, a decrease of about 41.29% compared to the same period last year; and the basic loss per share is around RMB 0.435.
The announcement stated that the reason for the decrease in losses is that in 2025, the situation in the steel industry has improved compared to the previous year, but the overall market supply remains strong and demand remains weak. Faced with market pressure, the company continues to promote the "focus on value creation, comprehensive accounting management" work, increase market development and quality adjustment efforts, improve operational efficiency, tap into energy potential, optimize procurement radius, focus on systematic cost reduction, and has arranged for major production lines to be significantly upgraded to improve market competitiveness. Overall, the operating situation is improving.
Related Articles

New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)

From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?

New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?
New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)

From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?

New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?

RECOMMEND

Multiple A‑Share Companies Update Hong Kong IPO Progress Since Start Of Year
30/01/2026

Mainland Pharmaceutical Companies Rush To Hong Kong, Over 10 Firms Queue For IPO
30/01/2026

2026 Hong Kong Market Faces Unlocking Peak: HKD 1.6 Trillion In Restricted Shares To Be Released, How Will The Market Respond?
30/01/2026


